Thermo Fisher Scientific (TMO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of eleven director nominees for the board for the upcoming term.
An advisory vote will be held to approve named executive officer compensation.
Ratification of PricewaterhouseCoopers LLP as independent auditors for 2026 is on the agenda.
Additional business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Eleven individuals have been nominated for election to the board, including Marc N. Casper and Karen S. Lynch.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Thermo Fisher Scientific
- Q2 2026 revenue up 10% to $11.99B, adjusted EPS up 13%, and $1B in stock repurchases.TMO
Q2 2026 - Director nominees elected, auditor ratified, executive pay not approved; strong growth and AI focus.TMO
AGM 2026 - Targets 3–6% organic growth for 2026–2027, fueled by AI, innovation, and accretive M&A.TMO
Investor Day 2026 - Executive compensation program revised for 2026 to enhance pay-for-performance and shareholder alignment.TMO
Proxy filing - Q1 2026 revenue rose 6% to $11.01B, adjusted EPS up 6%, and guidance was raised.TMO
Q1 2026 - 2025 saw strong growth, major compensation changes, and continued focus on governance and ESG.TMO
Proxy filing - Q3 revenue up 5% to $11.12B, adjusted EPS up 10%, with strong innovation and acquisitions.TMO
Q3 2025 - Targets 7–9% organic growth, margin expansion, and share gains through innovation and execution.TMO
Investor Day 2024 - Q2 revenue dipped 1% but EPS grew, and guidance was raised after the Olink acquisition.TMO
Q2 2024